Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Slight Boost Expected in IVD Industry

By LabMedica International staff writers
Posted on 26 Aug 2013
According to a recent report by healthcare market research publisher Kalorama Information (New York, NY, USA), the US Patient Protection and Affordable Care Act (PPACA) is expected to benefit the IVD and clinical lab test industry to some extent. More...
Sales are expected to rise an extra 1.3% more per year, in the next five years, than would have otherwise been seen without the law.

The Patient Protection and Affordable Care Act (H.R. 3590), passed in 2010 is complex legislation that affects virtually every aspect of health care, and many of its provisions are beginning to take effect now. The overall objective of the PPACA is to expand access to health care coverage for most US citizens and legal residents by requiring individuals to have coverage, and for employers to either provide coverage or pay a penalty that would support coverage from a pool of public funds.

The most significant IVD and clinical lab sales drivers resulting from the PPACA will be an expansion in the number of insured US persons, increased utilization of tests related to nosocomial infections, and new coverage of wellness and prevention programs. Kalorama also noted that the bill contains market restraints as well, and warned that many questions about implementation and future effects remain.

“The reform taketh away from IVD but you could say it ‘giveth’ a little more,” said Bruce Carlson, publisher of Kalorama Information. “Several key provisions of the PPACA, in combination with favorable population demographics, will stimulate IVD product sales. It’s an industry that lives or dies based on test procedure numbers and thus the growth in the number of persons with health care coverage is good news for IVD.”

The Kalorama report contains sales estimates for the historic 2012 period of the IVD market and forecasts are provided through 2022. It then analyzes the impact of various PPACA provisions on the IVD market. The report can be found online (please see Related Links: below).

Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices, and healthcare, as well as a full range of custom research services. Kalorama routinely assist the media with healthcare topics.

Related Links:

Kalorama Information
Report: The Impact of Healthcare Reform (PPACA) On the US IVD Industry



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Collection and Transport System
PurSafe Plus®
New
Human Estradiol Assay
Human Estradiol CLIA Kit
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.